PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-166.34%
Both yoy net incomes decline, with VET at -9.74%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
0.97%
Less D&A growth vs. VET's 41.16%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
98.45%
Some yoy growth while VET is negative at -62.90%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-9.09%
Both cut yoy SBC, with VET at -36.30%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
138.60%
Less working capital growth vs. VET's 333.51%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
42.17%
AR growth of 42.17% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
-120.00%
Negative yoy inventory while VET is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-37.70%
Negative yoy AP while VET is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
338.89%
Growth well above VET's 333.51%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
3010.00%
Well above VET's 20.88%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-9.31%
Negative yoy CFO while VET is 112.68%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-9.43%
Negative yoy CapEx while VET is 5.02%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
102000.00%
Some acquisitions while VET is negative at -3003.31%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-350.00%
Both yoy lines negative, with VET at -164.48%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
276.95%
We have mild expansions while VET is negative at -30.24%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-144.72%
Both yoy lines negative, with VET at -1.10%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.